Coskun Ozer Demirtas
Overview
Explore the profile of Coskun Ozer Demirtas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
163
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Demirtas C, Ozdogan O
Hepatol Forum
. 2022 Aug;
1(3):112-118.
PMID: 35949723
Patients with cirrhosis are at the highest risk to develop hepatocellular carcinoma (HCC), with a variable annual risk of 1-8%. Currently, biannual abdominal ultrasound (USG) with or without alpha fetoprotein...
12.
Demirtas C, Sapmaz A, Gurel B, Kizmaz H, Ulu T, Karaketir S, et al.
Hepatol Forum
. 2022 Aug;
1(3):101-108.
PMID: 35949721
Background And Aim: Non-alcoholic fatty liver disease (NAFLD) is closely associated with insulin resistance (IR). While a minority of patients with NAFLD does not have evidence of IR, no detailed...
13.
Kani H, Sener T, Aykut U, Demirtas C, Keklikkiran C, Ergenc I, et al.
Hepatol Forum
. 2022 Jul;
2(2):60-63.
PMID: 35783901
Background And Aim: Erectile dysfunction (ED) is an important and commonly seen disorder in patients with non-alcoholic fatty liver disease (NAFLD). The objective of this study was to assess the...
14.
Ergenc I, Gokcen P, Adali G, Kani H, Demirtas C, Gunduz F, et al.
Hepatol Forum
. 2022 Jul;
2(1):20-25.
PMID: 35782891
Background And Aim: The coexistence of metabolic-associated fatty liver disease (MAFLD) in the course of chronic hepatitis B virus infection increases liver-related morbidity. A positive correlation was found between positive...
15.
Demirtas C, Gunduz F
J Gastrointest Cancer
. 2021 Dec;
52(4):1217-1222.
PMID: 34897577
In recent years, immune-based therapies have emerged as novel pillars for hepatocellular carcinoma (HCC). The rationale of immune-checkpoint inhibitors (ICIs) trial in HCC originated from the fact that the tumor...
16.
Demirtas C, Gunduz F, Ozdogan O
J Gastrointest Cancer
. 2021 Dec;
52(4):1336-1339.
PMID: 34855124
Currently, international liver societies recommend screening at-risk individuals for HCC (patients with cirrhosis regardless of etiology, and/or chronic hepatitis B virus, and/or advanced liver fibrosis) with biannual abdominal ultrasound (USG)...
17.
Demirtas C, Vahabov C, Mustafayev F, Sahin T, Parlak E
Turk J Gastroenterol
. 2021 Nov;
32(10):879-887.
PMID: 34787093
Background: The Coronavirus-2019 disease (COVID-19) pandemic has markedly restricted endoscopic and clinical activities in gastroenterology (GI), with a negative impact on trainee education. We aimed to inve stigate how and...
18.
Demirtas C, Ricco G, Ozdogan O, Baltacioglu F, Ones T, Yumuk P, et al.
Hepatol Commun
. 2021 Nov;
6(3):633-645.
PMID: 34751001
Optimal scoring system for clinical prognostic factors in patients with unresectable hepatocellular carcinoma (HCC) is currently uncertain. We aimed to develop and externally validate an easy to use tool, particularly...
19.
Demirtas C, Brunetto M
World J Gastroenterol
. 2021 Sep;
27(33):5536-5554.
PMID: 34588750
Surveillance with abdominal ultrasound with or without alpha-fetoprotein is recommended by clinical practice guidelines for patients who are considered to be at risk of developing hepatocellular carcinoma (HCC), including those...
20.
Demirtas C, Tolu T, Keklikkiran C, Ozdogan O, Gunduz F
Turk J Gastroenterol
. 2021 Sep;
32(8):685-693.
PMID: 34528882
Background: A small proportion of all hepatocellular carcinomas (HCCs) arise in a non-cirrhotic liver (NCL). However, our knowledge about the HCCs developing in a NCL is scarce. This study was...